Table 5.
Severe adverse events and side effects profile (encompassing gut, bone marrow, and circulatory system) of primary and secondary GBM patients treated with nanotherapy.
| Major Type | Severe Adverse Events/Side Effects | Primary GBM (n = 66) | Secondary GBM (n = 159) |
Pooled (n = 225) |
|---|---|---|---|---|
| Gastrointestinal | Vomiting/nausea | 4 (6.06%) | 31 (19.5%) | 35 (15.56%) |
| Stomatitis | 2 (3.03%) | 0 | 2 (0.89%) |
|
| Gastritis | 2 (3.03%) | 0 | 2 (0.89%) |
|
| Diarrhea | 3 (4.54%) | 0 | 3 (1.33%) |
|
| Myelotoxicity | Leukopenia, lymphopenia, thrombocytopenia, neutropenia, anemia |
55 (83.33%) |
18 (11.32%) |
73 (32.44%) |
| Thromboembolic | Deep vein thrombosis | 2 (3.03%) | 1 (0.63%) | 3 (1.33%) |
| Pulmonary embolism | 1 (1.52%) | 0 | 1 (0.44%) |